Inhibition of MEK, a canonical KRAS pathway effector in KRAS mutant NSCLC.
Sign Up to like & getrecommendations! Published in 2018 at "Translational lung cancer research"
DOI: 10.21037/tlcr.2018.03.20
Abstract: KRAS mutant NSCLC cells require active nuclear export of Iκβα (also known as NFKBIA), a negative regulatory protein of NF-κB signaling, for maintaining survival signaling (1-3). Nuclear export receptor XPO1 correlates with KRAS mutation status. read more here.
Keywords: inhibition mek; mutant nsclc; canonical kras; kras mutant ... See more keywords
Synthetic Vulnerabilities in the KRAS Pathway
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14122837
Abstract: Simple Summary Despite recent dramatic progress, developing drugs that target oncogenic KRAS or its key effectors remains a major challenge for cancer research. Improving our understanding of the underlying biology of KRAS in cancer will… read more here.
Keywords: vulnerabilities kras; synthetic lethal; kras mutant; kras pathway ... See more keywords
KRAS Pathway Alterations in Malignant Pleural Mesothelioma: An Underestimated Player
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14174303
Abstract: Simple Summary Malignant pleural mesothelioma (MPM) is a rare, incurable cancer. KRAS pathway alterations are frequent in human MPM but have been likely underestimated by next generation sequencing studies. Abstract Malignant pleural mesothelioma (MPM) is… read more here.
Keywords: malignant pleural; pathway alterations; kras pathway; pleural mesothelioma ... See more keywords